Health
Study shows 90.7% efficacy for the BNT162b2 COVID vaccine in 5-11 year-olds – News-Medical.Net
A new study evaluates the safety, immunogenicity, and efficacy of the BNT162b2 in children who were 5 to 11 years of age.
Vaccination against coronavirus disease 2019 (COVID-19) has been considered to be the most effective way to reduce the mortality and morbidity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Several vaccine candidates have…
Continue Reading
-
Noosa News16 hours agoTammy Hembrow’s half-brother walks free after choking and stalking ex-girlfriend
-
Business16 hours agoGuess which ASX 300 stock was downgraded to sell today
-
Noosa News21 hours agoPolice hunt two after baby girl sprayed with stolen fire extinguisher in Sippy Downs
-
Business17 hours agoHow to start investing in ASX shares with just $1,000